Windlas Biotech Limited — PPTs, 11-02-2025: Investor Presentation

1. **Financial Highlights**: Windlas Biotech reported a robust performance with a revenue of Rs. 557.2 crore for the 9 months of FY25, marking a 21% increase year-on-year, and Rs. 195.0 crore for Q3, up 20% YoY. The EBITDA for the same periods surged to Rs. 68.6 crore (12.3% margin) and Rs. 24.6 crore (12.6% margin) respectively, indicating a 22% and 21% growth. The PAT stood at Rs. 44.7 crore, reflecting a 9% increase for 9M and Rs. 15.6 crore, up 3% YoY for Q3.

2. **Strategic Initiatives and Growth Drivers**: The company focuses on expanding its customer base and product offerings, especially in its Generic Formulations CDMO vertical, which reported a 15% growth to Rs. 407.9 crore in 9M FY25. The Trade Generics and Institutional vertical outperformed with a 44% increase, generating Rs. 126.6 crore.

3. **Business Developments**: Windlas received GMP certification for its injectables facility, paving the way for large customer audits, which are scheduled in Q4 FY25. Expansion of the plant has also been fully operational, enhancing production capabilities.

4. **Market Position and Competitive Advantage**: Windlas maintains a strong position within the growing Indian pharmaceutical market, driven by its diversified portfolio and strategic investments in R&D and production capabilities.

5. **Investor Implications**: The solid revenue growth and operational efficiencies suggest a positive outlook for Windlas Biotech, providing potential growth opportunities for investors, especially with the expanding Generic Formulations segment and successful market certifications.